FDA Approves Bayer's KERENDIA To Reduce UACR And Slow Chronic Kidney Disease Progression In Adults With Type 1 Diabetes
Share
Why It Matters
Bayer got permission to sell a kidney disease medicine for type 1 diabetes. This shows the drug works, which is good for the company's future sales.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.